Recent Updates
Recently added Catalysts
SMMT Positive Sentiment

Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

Wednesday, October 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Summit Therapeutics has partnered with ECOG-ACRIN to conduct a Phase II/III clinical trial evaluating ivonescimab in biliary tract cancer. The study, designated EA2251, aims to assess the safety and efficacy of ivonescimab in combination with chemotherapy against pembrolizumab or durvalumab. This collaboration marks a significant step in cancer treatment research.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration with ECOG-ACRIN Cancer Research Group
  • Evaluation of ivonescimab in biliary tract cancer
  • Potential first-in-class bispecific antibody
  • Registration-enabling Phase II/III study

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
39.8%
average across 4 past catalysts
Cash runway
~12 mo
Low dilution risk
Lead asset
Ivonescimab
NDA/BLA · Non-Squamous Non-small Cell Lung Cancer

Full Press Release Details

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in a registration-enabling Phase II/III study in biliary tract cancer (BTC). The new study, EA2251 (NCT07765433), is designed to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab pl

Frequently Asked Questions

What is the purpose of the EA2251 study?

The EA2251 study evaluates the safety and efficacy of ivonescimab in biliary tract cancer.

Who is collaborating with Summit Therapeutics?

Summit is collaborating with the ECOG-ACRIN Cancer Research Group.

What type of drug is ivonescimab?

Ivonescimab is a novel, potential first-in-class bispecific antibody.

What treatments is ivonescimab compared to in the trial?

It is compared to pembrolizumab or durvalumab in combination with chemotherapy.

ShareAdd on Google
Tags: SMMT Summit Therapeutics ECOG-ACRIN ivonescimab biliary tract cancer clinical trial
Last updated: Oct 21, 2026

Biotech snapshot

Cash runway
$691M liquidity · $47M/mo burn
~12 mo
Low dilution risk
Lead asset
IvonescimabNDA/BLA
Non-Squamous Non-small Cell Lung Cancer →

Catalyst track record

+48%
best trade around SMMT's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SMMT.

See every catalyst's timing & PoA →